Aida Batista - Academia.edu (original) (raw)
Papers by Aida Batista
European Journal of Hospital Pharmacy
Os biossimilares sao medicamentos biotecnologicos aprovados com qualidade, seguranca e eficacia c... more Os biossimilares sao medicamentos biotecnologicos aprovados com qualidade, seguranca e eficacia com paraveis aos medicamentos originais, com ausencia de diferencas relevantes nos parâmetros quimicos, biologicos, pre-clinicos e clinicos. Dentro destes, podemos separa-los entre biossimilares de primeira geracao (epoetinas, somatotropina, filgastrim) e os de segunda geracao (anticorpos). As razoes da popularidade dos anticorpos terapeuticos (mAb) biossimilares sao atribuiveis ao potencial do mercado destes produtos e ao facto das patentes de alguns mAb originais estarem a aproximar-se do final sua validade 1 . A potencial vantagem da entrada dos biossimilares podera residir num maior acesso dos doentes a medicamentos biotecnologicos dispendiosos. No entanto, a sua utilizacao clinica nao tem estado isenta de algumas preocupacoes 1,2,3 .
European Journal of Hospital Pharmacy, 2020
European Journal of Hospital Pharmacy, 2021
Aim The present survey aimed to collect information on the lessons learnt from the COVID-19 pande... more Aim The present survey aimed to collect information on the lessons learnt from the COVID-19 pandemic by hospital pharmacists. It focused on the shortages of health goods and the experiences of hospitals during the first phase of the crisis. Methods A 17-question survey was conducted by EAHP, looking at the experiences of hospital pharmacists during the COVD-19 pandemic. The survey ran from 16 September to 23 December 2020. Statistical analysis included backward stepwise logistic regression (BSLR), Pearson's χ 2 test, t-test and one-way ANOVA, as appropriate; p≤0.05 was considered statistically significant. Results 1466 hospital pharmacists answered the survey fully. 58%, 63% and 69% of them experienced shortages in medicines, disinfectants and personal protective equipment (PPE), respectively. BSLR showed that being a COVID-19 dedicated hospital increased the risk of medicine shortages (OR 1.63, 95% CI 1.15 to 2.31) but the shortages of disinfectants and PPE were lower (OR 0.62, 95% CI 0.44 to 0.88; OR 0.60, 95% CI 0.42 to 0.85). Being a specialised hospital reduced the odds of medicine shortages (OR 0.59, 95% CI 0.40 to 0.88), while countries with a greater percentage of the population infected had increased odds for all three types of shortages (OR 1.16, 95% CI 1.01 to 1.23; OR 1.34, 95% CI 1.19 to 1.50; OR 1.21, 95% CI 1.09 to 1.35). The odds were also higher in answers submitted in September compared with December. The classes of medicines with highest reported shortages were anaesthetics, antibiotics and muscle relaxants. The main entities that provided support were the national competent authorities and manufacturers. Conclusion Medicine shortages affected the work of hospital pharmacists during the early stages of the pandemic. The features of the crisis and the feedback described in this survey can provide interesting insights for a more resilient healthcare framework in the future.
EAHP’s position paper advocates for the involvement of hospital pharmacists in procurement. The i... more EAHP’s position paper advocates for the involvement of hospital pharmacists in procurement. The immediate concern of any hospital pharmacist is to ensure that every patient within the hospital receives the medications needed. For this reason, hospital pharmacists have a direct stake in the efficient functioning of the medicines’ supply chain. The position touches on pharmaceutical tendering which is a complex process that involves different stakeholders and steps that are regulated at national level leading to diverse solutions in the different European countries. In addition, these processes are guided by publications of other international actors such as the World Health Organisation (WHO) and the Organisation for Economic Co-operation and Development (OECD). The second part focuses on the role of hospital pharmacists in procurement which due to their knowledge and skills are specialists in the field of all medicines’ procurement. Hospital pharmacists should lead in all phases of ...
Journal of clinical pharmacy and therapeutics, 2017
Biopharmaceuticals are an important class of drugs for the treatment of autoimmune/inflammatory a... more Biopharmaceuticals are an important class of drugs for the treatment of autoimmune/inflammatory and oncologic diseases. With patent expiries, biotechnological manufacturers can now develop biosimilar drugs. Due to timeliness of introducing new and more complex biosimilars, the Portuguese Association of Hospital Pharmacists gathered to develop a common positioning on the use of biosimilar monoclonal antibodies. The European pathway to biosimilar approval was developed to improve affordability and access to biological therapies, but it remains a work in progress because unresolved issues remain. Due to the present reality of biosimilar monoclonal antibodies, hospital pharmacists must play an important role in ensuring the safe, effective and cost-effective use of biosimilars in health systems; and educating healthcare administrators, providers, legislators, policymakers, payors and patients about these products. The conclusions presented in this work focused on the proposal for optima...
Os biossimilares são medicamentos biotecnológicos aprovados com qualidade, segurança e eficácia c... more Os biossimilares são medicamentos biotecnológicos aprovados com qualidade, segurança e eficácia com-paráveis aos medicamentos originais, com ausência de diferenças relevantes nos parâmetros químicos, biológicos, pré-clínicos e clínicos. Dentro destes, po-demos separá-los entre biossimilares de primeira ge-ração (epoetinas, somatotropina, filgastrim) e os de segunda geração (anticorpos). As razões da popula-ridade dos anticorpos terapêuticos (mAb) biossimi-lares são atribuíveis ao potencial do mercado destes produtos e ao facto das patentes de alguns mAb ori-ginais estarem a aproximar-se do final sua validade 1. A potencial vantagem da entrada dos biossimilares poderá residir num maior acesso dos doentes a medi-camentos biotecnológicos dispendiosos. No entanto, a sua utilização clínica não tem estado isenta de algu-mas preocupações 1,2,3. O termo biossimilar é um conceito regulamentar ba-seado em critérios de qualidade, eficácia e segurança. O desenvolvimento de biossimilares de anti...
European Journal of Hospital Pharmacy, Dec 2, 2019
European Journal of Hospital Pharmacy
European Journal of Hospital Pharmacy
Pharmaceutical Supply Chains - Medicines Shortages
European Journal of Hospital Pharmacy
European Journal of Hospital Pharmacy
European Journal of Hospital Pharmacy
European Journal of Hospital Pharmacy
European Journal of Hospital Pharmacy
European Journal of Hospital Pharmacy, 2014
European Journal of Hospital Pharmacy
Os biossimilares sao medicamentos biotecnologicos aprovados com qualidade, seguranca e eficacia c... more Os biossimilares sao medicamentos biotecnologicos aprovados com qualidade, seguranca e eficacia com paraveis aos medicamentos originais, com ausencia de diferencas relevantes nos parâmetros quimicos, biologicos, pre-clinicos e clinicos. Dentro destes, podemos separa-los entre biossimilares de primeira geracao (epoetinas, somatotropina, filgastrim) e os de segunda geracao (anticorpos). As razoes da popularidade dos anticorpos terapeuticos (mAb) biossimilares sao atribuiveis ao potencial do mercado destes produtos e ao facto das patentes de alguns mAb originais estarem a aproximar-se do final sua validade 1 . A potencial vantagem da entrada dos biossimilares podera residir num maior acesso dos doentes a medicamentos biotecnologicos dispendiosos. No entanto, a sua utilizacao clinica nao tem estado isenta de algumas preocupacoes 1,2,3 .
European Journal of Hospital Pharmacy, 2020
European Journal of Hospital Pharmacy, 2021
Aim The present survey aimed to collect information on the lessons learnt from the COVID-19 pande... more Aim The present survey aimed to collect information on the lessons learnt from the COVID-19 pandemic by hospital pharmacists. It focused on the shortages of health goods and the experiences of hospitals during the first phase of the crisis. Methods A 17-question survey was conducted by EAHP, looking at the experiences of hospital pharmacists during the COVD-19 pandemic. The survey ran from 16 September to 23 December 2020. Statistical analysis included backward stepwise logistic regression (BSLR), Pearson's χ 2 test, t-test and one-way ANOVA, as appropriate; p≤0.05 was considered statistically significant. Results 1466 hospital pharmacists answered the survey fully. 58%, 63% and 69% of them experienced shortages in medicines, disinfectants and personal protective equipment (PPE), respectively. BSLR showed that being a COVID-19 dedicated hospital increased the risk of medicine shortages (OR 1.63, 95% CI 1.15 to 2.31) but the shortages of disinfectants and PPE were lower (OR 0.62, 95% CI 0.44 to 0.88; OR 0.60, 95% CI 0.42 to 0.85). Being a specialised hospital reduced the odds of medicine shortages (OR 0.59, 95% CI 0.40 to 0.88), while countries with a greater percentage of the population infected had increased odds for all three types of shortages (OR 1.16, 95% CI 1.01 to 1.23; OR 1.34, 95% CI 1.19 to 1.50; OR 1.21, 95% CI 1.09 to 1.35). The odds were also higher in answers submitted in September compared with December. The classes of medicines with highest reported shortages were anaesthetics, antibiotics and muscle relaxants. The main entities that provided support were the national competent authorities and manufacturers. Conclusion Medicine shortages affected the work of hospital pharmacists during the early stages of the pandemic. The features of the crisis and the feedback described in this survey can provide interesting insights for a more resilient healthcare framework in the future.
EAHP’s position paper advocates for the involvement of hospital pharmacists in procurement. The i... more EAHP’s position paper advocates for the involvement of hospital pharmacists in procurement. The immediate concern of any hospital pharmacist is to ensure that every patient within the hospital receives the medications needed. For this reason, hospital pharmacists have a direct stake in the efficient functioning of the medicines’ supply chain. The position touches on pharmaceutical tendering which is a complex process that involves different stakeholders and steps that are regulated at national level leading to diverse solutions in the different European countries. In addition, these processes are guided by publications of other international actors such as the World Health Organisation (WHO) and the Organisation for Economic Co-operation and Development (OECD). The second part focuses on the role of hospital pharmacists in procurement which due to their knowledge and skills are specialists in the field of all medicines’ procurement. Hospital pharmacists should lead in all phases of ...
Journal of clinical pharmacy and therapeutics, 2017
Biopharmaceuticals are an important class of drugs for the treatment of autoimmune/inflammatory a... more Biopharmaceuticals are an important class of drugs for the treatment of autoimmune/inflammatory and oncologic diseases. With patent expiries, biotechnological manufacturers can now develop biosimilar drugs. Due to timeliness of introducing new and more complex biosimilars, the Portuguese Association of Hospital Pharmacists gathered to develop a common positioning on the use of biosimilar monoclonal antibodies. The European pathway to biosimilar approval was developed to improve affordability and access to biological therapies, but it remains a work in progress because unresolved issues remain. Due to the present reality of biosimilar monoclonal antibodies, hospital pharmacists must play an important role in ensuring the safe, effective and cost-effective use of biosimilars in health systems; and educating healthcare administrators, providers, legislators, policymakers, payors and patients about these products. The conclusions presented in this work focused on the proposal for optima...
Os biossimilares são medicamentos biotecnológicos aprovados com qualidade, segurança e eficácia c... more Os biossimilares são medicamentos biotecnológicos aprovados com qualidade, segurança e eficácia com-paráveis aos medicamentos originais, com ausência de diferenças relevantes nos parâmetros químicos, biológicos, pré-clínicos e clínicos. Dentro destes, po-demos separá-los entre biossimilares de primeira ge-ração (epoetinas, somatotropina, filgastrim) e os de segunda geração (anticorpos). As razões da popula-ridade dos anticorpos terapêuticos (mAb) biossimi-lares são atribuíveis ao potencial do mercado destes produtos e ao facto das patentes de alguns mAb ori-ginais estarem a aproximar-se do final sua validade 1. A potencial vantagem da entrada dos biossimilares poderá residir num maior acesso dos doentes a medi-camentos biotecnológicos dispendiosos. No entanto, a sua utilização clínica não tem estado isenta de algu-mas preocupações 1,2,3. O termo biossimilar é um conceito regulamentar ba-seado em critérios de qualidade, eficácia e segurança. O desenvolvimento de biossimilares de anti...
European Journal of Hospital Pharmacy, Dec 2, 2019
European Journal of Hospital Pharmacy
European Journal of Hospital Pharmacy
Pharmaceutical Supply Chains - Medicines Shortages
European Journal of Hospital Pharmacy
European Journal of Hospital Pharmacy
European Journal of Hospital Pharmacy
European Journal of Hospital Pharmacy
European Journal of Hospital Pharmacy
European Journal of Hospital Pharmacy, 2014